Health Condition 1: F209- Schizophrenia, unspecified
Conditions
Interventions
Intervention1: Quetiapine film coated tablets 300 mg (as quetiapine fumarate): Twice daily per day
Patient will receive test drug for 5 consecutive days followed by reference product for another 5 con
Sponsors
Hetero Labs Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient has a documented clinical diagnosis of schizophrenia (DSM IV-TR) and on a stable dose of Quetiapine 600 mg per day for at least 10 days prior to screening. 2. Having a Body Mass Index (BMI) between 18 and 30 (both inclusive), calculated as weight in kg / height in m2. 3. The investigator must ensure that the respective hepatic, renal, haematopoietic, cardiac and respiratory functions are appropriate to include the patient in the study. 4. Able to comply with study procedures in the opinion of the investigator. 5. Sexually active women, unless surgically sterile (at least 6 months prior to Study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician. 6. In case of Male patients: Either partner or patient must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity or idiosyncratic reaction to Quetiapine and its excipients. 2. Current or relevant history of serious, severe or unstable psychiatric illness except schizophrenia. 3. Presence of Postural Hypotension (Defined as systolic blood pressure decrease of at least 20 mmHg or a diastolic blood pressure decrease of at least 10 mmHg within three minutes of standing up). 4. History of syncope or orthostatic hypotension. 5. A recent history of alcoholism (less than 2 years) or daily consumption of moderate (180 mL/day) alcohol use, or consumption of alcohol or alcoholic products within 48 hour prior to receiving study medication or inability to abstain from alcohol during the study. 6. Smokers who has inability to abstain from smoking during the study. 7. Known case of HIV infection. 8. Any condition/ Abnormal baseline findings that in the investigatorâ??s judgement might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to obtain the objective of the study. 9. Hospitalisation for an exacerbation of schizophrenia within two months prior to screening and during the screening period. 10. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others. 11. History of agranulocytosis. 12. Pregnant or lactating females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the bioavailability and characterise the pharmacokinetic profile of the Sponsorâ??s formulation (Quetiapine film coated tablets 300 mg) with respect to the reference formulation (Seroquel® film coated 300 mg tablets) in adult Schizophrenic patients (stabilized on Quetiapine 600 mg per day) under fasting conditions and to assess the bioequivalence.Timepoint: - | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor the safety of the patients who are exposed to the investigational medicinal product.Timepoint: _ | — |
Countries
India
Contacts
Public ContactDr Praveen Shetty
Lambda Therapeutic Research Ltd
Outcome results
None listed